David Shapiro was appointed Director of Design Therapeutics, Inc. As of November 6, 2026, Design Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 1, 2026, naming 1 appointment (Form 8-K, April 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Design Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Design Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-01. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Design Therapeutics, Inc. files it.
Also on the record for Design Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 3.8% of the class | 5%+ stakes | Source |
| June 9, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 4.4% of the class | 5%+ stakes | Source |
| March 11, 2026 | Stake report, Schedule 13D/A, by SR One Capital Fund I Aggregator, LP | 10.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 9.4% of the class | 5%+ stakes | Source |
| November 18, 2025 | Stake report, Schedule 13D/A, by Logos Global Management LP | 4.4% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13D/A, by Logos Global Management LP | 5.7% of the class | 5%+ stakes | Source |
| August 28, 2025 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Design Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Design Therapeutics, Inc. and the records around it.
Design Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Design Therapeutics, Inc.
Get an email when Design Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Design Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Design Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Design Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-01 | In | Director | 8-K, 2026-04-01 |
Who leads Design Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David Shapiro, appointed (filed 2026-04-01).
New leaders reset buying decisions — get the Full Report on Design Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Design Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Design Therapeutics, Inc.Every change, in the filing's words
Appointed: David Shapiro, Director
On March 31, 2026, the Board appointed David Shapiro, M.D., to the Board as a Class III director, effective immediately, with a term ending at the Company's 2027 annual meeting of stockholders.
- Dr. Shapiro was also appointed to the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee").
- Pursuant to the Company's current non-employee director compensation policy, (i) Dr. Shapiro is entitled to receive an annual cash retainer of (a) $40,000 for service on the Board and (b) $5,000 for service as a member of the Nominating Committee, and (ii) Dr. Shapiro received (a) an initial option grant to purchase 60,000 shares of our common stock, which vests monthly over a three-year period, and (b) a prorated annual option grant to purchase 7,500 shares of our common stock, which vests monthly over a one-year period.
Tools for this story
Each opens in a new tab, filled in for Design Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.